Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Venture Fund Ix, L.p. Arch currently holds 16,000 shares of Lyell Immunopharma, Inc. (LYEL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Venture Fund Ix, L.p. Arch has been a net seller of LYEL stock. They have purchased $0 and sold $39.8K worth of shares.
Venture Fund Ix, L.p. Arch's most recent insider trade was on Jul 1, 2026, when they sold 16,000 shares at $0.00 per share.
Venture Fund Ix, L.p. Arch serves as Executive at Lyell Immunopharma, Inc. (LYEL). They have executed 34 insider transactions totaling $39.8K over their tenure at the company.
Venture Fund Ix, L.p. Arch holds the position of Executive at Lyell Immunopharma, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 5 years and currently hold a stake valued at $0.
Venture Fund Ix, L.p. Arch has shown a selling trading pattern, with $0 in total purchases and $39.8K in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Venture Fund Ix, L.p. Arch was on Jul 1, 2026, when they sold $39.8K worth of BOLD shares. This transaction involved 16,000 shares at $2.49 per share.
Venture Fund Ix, L.p. Arch currently owns 16,000 shares of Lyell Immunopharma, Inc. (LYEL), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Venture Fund Ix, L.p. Arch's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Venture Fund Ix, L.p. Arch has 34 Form 4 filings on record as an insider at Lyell Immunopharma, Inc..
Set alerts for Venture Fund Ix, L.p. Arch and 40,000+ other insiders.